{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:30:27Z","timestamp":1791174627721,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T00:00:00Z","timestamp":1256515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The predictive value of molecular minimal residual disease (MRD) monitoring using polymerase chain reaction amplification of clone\u2010specific immunoglobulin or T\u2010cell Receptor rearrangements was analysed in 161 patients with non T\u2010lineage Philadelphia\u2010negative acute lymphoblastic leukaemia (ALL) participating in the UK arm of the international ALL trial UKALL XII\/Eastern Cooperative Oncology Group (ECOG) 2993. MRD positivity (\u226510<jats:sup>\u22124<\/jats:sup>) in patients treated with chemotherapy alone was associated with significantly shorter relapse\u2010free survival (RFS) at several time\u2010points during the first year of therapy. MRD status best discriminated outcome after phase 2 induction, when the relative risk of relapse was 8\u00b795 (2\u00b785\u201328\u00b709)\u2010fold higher in MRD\u2010positive (\u226510<jats:sup>\u22124<\/jats:sup>) patients and the 5\u2010year RFS 15% [95% confidence interval (CI) 0\u201340%] compared to 71% (56\u201385%) in MRD\u2010negative (&lt;10<jats:sup>\u22124<\/jats:sup>) patients (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b70002) When MRD was detected prior to autologous stem cell transplantation (SCT), a significantly higher rate of treatment failure was observed [5\u2010year RFS 25% (CI 0\u201355%) vs. 77% (95% CI 54\u2013100%) in MRD\u2010negative\/&lt;10<jats:sup>\u22124<\/jats:sup>, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b701] whereas in recipients of allogeneic\u2010SCT in first complete remission, MRD positivity pre\u2010transplant did not adversely affect outcome. These data provide a rationale for introducing MRD\u2010based risk stratification in future studies for the delineation of those at significant risk of treatment failure in whom intensification of therapy should be evaluated.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07941.x","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T01:49:15Z","timestamp":1256608155000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Minimal residual disease is a significant predictor of treatment failure in non T\u2010lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993"],"prefix":"10.1111","volume":"148","author":[{"given":"Bella","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeasmin","family":"Mortuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Gerrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Victor","family":"Hoffbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele K.","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.","family":"Goldstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,14]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.V86.4.1619.bloodjournal8641619","article-title":"Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin\u20102 after autologous bone marrow transplantation. BGMT Group","volume":"86","author":"Attal M.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390904"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.289831.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2691"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1952"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403103"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3560"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4072"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703659"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701976"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1094"},{"key":"e_1_2_5_18_1","first-page":"3281","article-title":"Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T\u2010cell receptor loci by LightCycler technology","volume":"60","author":"Nakao M.","year":"2000","journal-title":"Cancer Research"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1253"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401245"},{"key":"e_1_2_5_21_1","first-page":"222","article-title":"Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL\u201089). Spanish Society of Hematology","volume":"83","author":"Ribera J.M.","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2002.3311a.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2580"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10965"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401071"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.050"},{"key":"e_1_2_5_28_1","first-page":"449","article-title":"Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia","volume":"12","author":"Tiley C.","year":"1993","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291802"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402475"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2613"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07941.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07941.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:23:53Z","timestamp":1697412233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07941.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07941.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07941.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,14]]},"assertion":[{"value":"2009-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}